Tablets, Syrup (Sugar free, Alcohol free) Bronchial Mucolytic

COMPOSITION

Tablets

Each tablet contains:

Active ingredient: Bromhexine HCI 8mg

Excipients: Lactose, starch, gelatin, and magnesium stearate.

Syrup

Each teaspoonful (5ml) contains:

Active ingredient: Bromhexine HCI 4mg

Excipients: Glycerol, benzoic acid, tartaric acid, sodium carboxymethyl cellulose, sorbitol, fruit flavour, and purified water.

MUCOLYTE contains bromhexine which is a synthetic derivative of vasicine (the main active principle of the leaves of Adhatoda vasica).

Bromhexine has an excellent mucolytic effect and is mainly used in the treatment of bronchitis and other respiratory disorders, it acts by changing the structure of bronchial secretions thus reducing the viscosity and increasing the volume of sputum.

For full therapeutic effect. MUCOLYTE should be administered for several days until the patient experiences easier coughing and respiration. It is also given without hesitation for longer periods in chronic respiratory disease conditions.

INDICATIONS

MUCOLYTE liquefies the viscous mucus and is indicated in the following conditions:

- Tracheobronchitis

- Bronchitis with emphysema

- Bronchiectasis

- Bronchitis with bronchospasm

- Chronic inflammatory pulmonary conditions

- Pneumoconiosis

DOSAGE

- The doses and duration of treatment depend upon the severity of the condition.

- Adults and children over 10 years: 1-2 tablets 3 times daily or 10-20ml 3 times daily.

- Children: 5ml 3 times daily.

- Infants & babies: 2.5ml 3 times daily or as directed by the physician.

ADVERSE EFFECTS

- Clinically, bromhexine has been established as a safe drug if administered within the recommended doses. However, some side effects such as headache and nausea are experienced with overdosage.

PRESENTATIONS

Tablets: Packs of 20 tablets. (500 or 1000 tablets) in a hospital pack.

Syrup: Bottles of 100ml.

ZYTIGA® (abiraterone acetate)

Tablet 250 mg

INDICATIONS

ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with

• metastatic castration-resistant prostate cancer (CRPC).

• metastatic high-risk castration-sensitive prostate cancer (CSPC).

DOSAGE AND ADMINISTRATION

Metastatic castration-resistant prostate cancer:

• ZYTIGA 1,000 mg orally once daily with prednisone 5 mg orally twice daily.

Metastatic castration-sensitive prostate cancer:

• ZYTIGA 1,000 mg orally once daily with prednisone 5 mg orally once daily.

Patients receiving ZYTIGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ZYTIGA must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.

Dose Modification:

• For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the ZYTIGA

starting dose to 250 mg once daily.

• For patients who develop hepatotoxicity during treatment, hold ZYTIGA until recovery. Retreatment may be initiated at a reduced dose. ZYTIGA should be discontinued if patients develop severe hepatotoxicity.

CONTRAINDICATIONS

• Pregnancy.

ADVERSE REACTIONS

The most common adverse reactions (≥10%) are fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot fush, diarrhea, vomiting, upper respiratory infection, cough, and headache.

The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, and hypokalemia.

WARNINGS AND PRECAUTIONS

• Mineralocorticoid excess: Closely monitor patients with cardiovascular disease. Control hypertension and correct hypokalemia before treatment. Monitor blood pressure, serum potassium and symptoms of fluid retention at least monthly.

• Adrenocortical insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency.

Increased dosage of corticosteroids may be indicated before, during and after stressful situations.

• Hepatotoxicity: Can be severe and fatal. Monitor liver function and modify, interrupt, or discontinue

ZYTIGA dosing as recommended.

STORAGE

Store at 20°C to 25°C.

Keep out of reach of children.

 

⇐ Предыдущая1234567

Поделиться: